Review of pharmacologic and immunologic agents in the management of COVID-19

Zhu, 2020, A novel coronavirus from patients with pneumonia in China, 2019, N. Engl. J. Med., 382, 727, 10.1056/NEJMoa2001017 Gorbalenya, 2020, The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2, Nat. Microbiol., 5, 536, 10.1038/s41564-020-0695-z Rothan, 2020, The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak, J. Autoimmun., 109, 102433, 10.1016/j.jaut.2020.102433 Zhou, 2020, A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature, 579, 270, 10.1038/s41586-020-2012-7 Wang, 2020, Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures, J. Med. Virol., 92, 568, 10.1002/jmv.25748 Lai, 2020, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges, Int. J. Antimicrob. Agents, 55, 105924, 10.1016/j.ijantimicag.2020.105924 Scavone, 2020, Current pharmacological treatments for COVID-19: What’s next?, Br. J. Pharmacol., 177, 4813, 10.1111/bph.15072 Wu, 2020, An update on current therapeutic drugs treating COVID-19, Curr. Pharmacol. Reports., 6, 56, 10.1007/s40495-020-00216-7 Aljofan, 2020, COVID-19 treatment: the race against time, Electron. J. Gen. Med., 17, 10.29333/ejgm/7890 Dhama, 2020, COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics, Hum. Vaccines Immunother., 16, 1232, 10.1080/21645515.2020.1735227 Li, 2020, Therapeutic options for the 2019 novel coronavirus (2019-nCoV), Nat. Rev. Drug Discov., 19, 149, 10.1038/d41573-020-00016-0 Sham, 1998, ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease, Antimicrob. Agents Chemother., 42, 3218, 10.1128/AAC.42.12.3218 Cao, 2020, A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19, N. Engl. J. Med., 382, 1787, 10.1056/NEJMoa2001282 Lim, 2020, Case of the index patient who caused tertiary transmission of coronavirus disease 2019 in Korea: the application of Lopinavir/ritonavir for the treatment of COVID-19 pneumonia monitored by quantitative RT-PCR, J. Korean Med. Sci., 35 Siegel, 2017, Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1- f ][triazin-4-amino] Adenine C -Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses, J. Med. Chem., 60, 1648, 10.1021/acs.jmedchem.6b01594 Wang, 2020, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res., 30, 269, 10.1038/s41422-020-0282-0 Dubert, 2020, Case report study of the first five COVID-19 patients treated with remdesivir in France, Int. J. Infect. Dis., 98, 290, 10.1016/j.ijid.2020.06.093 Pastick, 2020, Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19), Open Forum Infect. Dis., 7, 10.1093/ofid/ofaa130 Alanagreh, 2020, The human coronavirus disease COVID-19: its origin, characteristics, and insights into potential drugs and its mechanisms, Pathogens., 9, 331, 10.3390/pathogens9050331 Pécheur, 2016, The synthetic antiviral drug Arbidol inhibits globally prevalent pathogenic viruses, J. Virol., 90, 3086, 10.1128/JVI.02077-15 Lian, 2020, Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study, Clin. Microbiol. Infect., 26, 917, 10.1016/j.cmi.2020.04.026 Cai, 2020, Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study, Engineering, 6, 1192, 10.1016/j.eng.2020.03.007 Chen, 2020 NCT04336904 Dong, 2020, Discovering drugs to treat coronavirus disease 2019 (COVID-19), Drug Discov. Ther., 14, 58, 10.5582/ddt.2020.01012 Govorkova, 2010, Combination chemotherapy for influenza, Viruses., 2, 1510, 10.3390/v2081510 Chiba, 2020, Effect of early oseltamivir on COVID-19-suspected outpatients without hypoxia, Res. Sq. Wang, 2020, Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China, JAMA - J. Am. Med. Assoc., 323, 1061, 10.1001/jama.2020.1585 Xu, 2020, Broad Spectrum antiviral agent Niclosamide and its therapeutic potential, ACS Infect. Dis., 6, 909, 10.1021/acsinfecdis.0c00052 Gassen, 2019, SKP2 attenuates autophagy through Beclin1-ubiquitination and its inhibition reduces MERS-coronavirus infection, Nat. Commun., 10, 5770, 10.1038/s41467-019-13659-4 Caly, 2020, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antivir. Res., 178, 104787, 10.1016/j.antiviral.2020.104787 Rossignol, 2016, Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus, J Infect Public Heal., 9, 227, 10.1016/j.jiph.2016.04.001 Cao, 2015, A screen of the NIH clinical collection small molecule library identifies potential anti-coronavirus drugs, Antivir. Res., 114, 1, 10.1016/j.antiviral.2014.11.010 Alessandri, 2018, The role of rescue therapies in the treatment of severe ARDS, Respir. Care, 63, 92, 10.4187/respcare.05752 S. Åkerström, M. Mousavi-Jazi, J. Klingström, M. Leijon, Å. Lundkvist, A. Mirazimi, Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus, J. Virol. 79 (2005) 1966–1969, https://doi.org.10.1128/JVI.79.3.1966-1969.2005 Chen, 2004, Inhalation of nitric oxide in the treatment of severe acute respiratory syndrome: a rescue trial in Beijing, Clin. Infect. Dis., 39, 1531, 10.1086/425357 Alhazzani, 2020, Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19), Intensive Care Med., 46, 854, 10.1007/s00134-020-06022-5 Parnham, 2014, Azithromycin: mechanisms of action and their relevance for clinical applications, Pharmacol. Ther., 143, 225, 10.1016/j.pharmthera.2014.03.003 Bosseboeuf, 2018, Azithromycin inhibits the replication of Zika virus, J. Antivir. Antiretrovir., 10, 6, 10.4172/1948-5964.1000173 Madrid, 2016, Evaluation of Ebola virus inhibitors for drug repurposing, ACS Infect. Dis., 1, 317, 10.1021/acsinfecdis.5b00030 Gautret, 2020, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int. J. Antimicrob. Agents, 56, 10.1016/j.ijantimicag.2020.105949 Lane, 2020, Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study, MedRxiv Li, 2017, National Influenza Apdm09 Clinical Investigation Group of, Effect of low-to-moderate-dose corticosteroids on mortality of hospitalized adolescents and adults with influenza A(H1N1)pdm09 viral pneumonia, Influenza Other Respir. Viruses, 11, 345, 10.1111/irv.12456 Siemieniuk, 2015, Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: A systematic review and meta-analysis, Ann. Intern. Med., 163, 519, 10.7326/M15-0715 Wu, 2004, Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide, Antimicrob. Agents Chemother., 48, 2693, 10.1128/AAC.48.7.2693-2696.2004 Russell, 2020, Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury, Lancet, 395, 473, 10.1016/S0140-6736(20)30317-2 Huang, 2020, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, 395, 497, 10.1016/S0140-6736(20)30183-5 Xu, 2020, Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series, BMJ., 368, m606, 10.1136/bmj.m606 Villar, 2020, Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial, Lancet Respir. Med., 8, 267, 10.1016/S2213-2600(19)30417-5 World Health Organization Arabi, 2018, Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome, Am. J. Respir. Crit. Care Med., 197, 757, 10.1164/rccm.201706-1172OC Amici, 2006, Indomethacin has a potent antiviral activity against SARS coronavirus, Antivir. Ther., 11, 1021, 10.1177/135965350601100803 Fang, 2020, Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?, Lancet Respir. Med., 8, e21, 10.1016/S2213-2600(20)30116-8 Turner, 2004, ACE2: from vasopeptidase to SARS virus receptor, Trends Pharmacol. Sci., 25, 291, 10.1016/j.tips.2004.04.001 Y. Wan, J. Shang, R. Graham, R.S. Baric, F. Li, Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus, J. Virol. 94 (2020), e00127–20. https://doi.org/10.1128/JVI.00127-20. Zheng, 2020, COVID-19 and the cardiovascular system, Nat. Rev. Cardiol., 17, 259, 10.1038/s41569-020-0360-5 Ferrario, 2005, Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2, Circulation., 111, 2605, 10.1161/CIRCULATIONAHA.104.510461 Smyth, 2019, Genetic associations between genes in the renin-angiotensin-aldosterone system and renal disease: A systematic review and meta-analysis, BMJ Open, 9, 10.1136/bmjopen-2018-026777 Carr, 2017, Vitamin C and immune function, Nutrients., 9, 1211, 10.3390/nu9111211 Van Gorkom, 2018, Influence of vitamin C on lymphocytes: an overview, Antioxidants., 7, 41, 10.3390/antiox7030041 Kim, 2013, Vitamin C is an essential factor on the anti-viral immune responses through the production of interferon-α/β at the initial stage of influenza A virus (H3N2) infection, Immune Netw., 13, 70, 10.4110/in.2013.13.2.70 Cheng, 2020, Can early and high intravenous dose of vitamin C prevent and treat coronavirus disease 2019 (COVID-19)?, Med. Drug Discov., 5, 100028, 10.1016/j.medidd.2020.100028 PDQ Integrative, Alternative, and Complementary Therapies Editorial Board, High-Dose Vitamin C (PDQ®): Health Professional Version, PDQ Cancer Information Summaries, National Cancer Institute (US), http://www.ncbi.nlm.nih.gov/pubmed/26389504, 2000 (accessed 20 June 2020). Aranow, 2011, Vitamin D and the immune system, J. Investig. Med., 59, 881, 10.2310/JIM.0b013e31821b8755 Grant, 2020, Evidence that vitamin d supplementation could reduce risk of influenza and covid-19 infections and deaths, Nutrients, 12, 988, 10.3390/nu12040988 Prasad, 2008, Zinc in human health: effect of zinc on immune cells, Mol. Med., 14, 353, 10.2119/2008-00033.Prasad Keyhan, 2020, Dysosmia and dysgeusia due to the 2019 novel coronavirus; a hypothesis that needs further investigation, Maxillofac. Plast. Reconstr. Surg., 42, 9, 10.1186/s40902-020-00254-7 Lechien, 2020, Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study, Eur. Arch. Oto-Rhino-Laryngol., 277, 2251, 10.1007/s00405-020-05965-1 Doty, 2019, Treatments for smell and taste disorders: A critical review, in: Handb, Clin. Neurol., 164, 455 te Velthuis, 2010, Zn2+ inhibits coronavirus and Arterivirus RNA polymerase activity in vitro and zinc Ionophores block the replication of these viruses in cell culture, PLoS Pathog., 6, 10.1371/journal.ppat.1001176 Tang, 2020, Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia, J. Thromb. Haemost., 18, 844, 10.1111/jth.14768 Mycroft-West, 2020, The 2019 coronavirus (SARS-CoV-2) surface protein (Spike) S1 Receptor Binding Domain undergoes conformational change upon heparin binding, BioRxiv Shi, 2020 Tang, 2020, Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy, J. Thromb. Haemost., 18, 1094, 10.1111/jth.14817 Rico-Mesa, 2020, The role of anticoagulation in COVID-19-induced hypercoagulability, Curr. Cardiol. Rep., 22, 53, 10.1007/s11886-020-01328-8 Thachil, 2020, ISTH interim guidance on recognition and management of coagulopathy in COVID-19, J. Thromb. Haemost., 18, 1023, 10.1111/jth.14810 Bonam, 2020, Adjunct immunotherapies for the Management of Severely ill COVID-19 patients, Cell Rep. Med., 1, 100016, 10.1016/j.xcrm.2020.100016 Wan, 2020 Tanaka, 2016, Immunotherapeutic implications of IL-6 blockade for cytokine storm, Immunotherapy., 8, 959, 10.2217/imt-2016-0020 Zhong, 2020, The immunology of COVID-19: is immune modulation an option for treatment?, Lancet Rheumatol., 2, e428, 10.1016/S2665-9913(20)30120-X Choi, 2018, Effects of Tocilizumab therapy on serum Interleukin-33 and Interleukin-6 levels in patients with rheumatoid arthritis, Arch. Rheumatol., 33, 389, 10.5606/ArchRheumatol.2018.6753 Xu, 2020, Effective treatment of severe COVID-19 patients with tocilizumab, Proc. Natl. Acad. Sci., 117, 10970, 10.1073/pnas.2005615117 Bersanelli, 2020, Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors, Immunotherapy., 12, 269, 10.2217/imt-2020-0067 NCT04357860 NCT04359901 Wang, 2020, Definition and risks of cytokine release syndrome in 11 critically ill COVID-19 patients with pneumonia: analysis of disease characteristics, J. Infect. Dis., 222, 1444, 10.1093/infdis/jiaa387 NCT04330638 Taylor, 2019, Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis, Rheumatology., 58, i17, 10.1093/rheumatology/key225 Broglie, 2017, Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis, Blood Adv., 1, 1533, 10.1182/bloodadvances.2017007526 Richardson, 2020, Baricitinib as potential treatment for 2019-{nCoV} acute respiratory disease, Lancet., 395, e30, 10.1016/S0140-6736(20)30304-4 Coleman, 2016, Abelson kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and Middle East respiratory syndrome coronavirus fusion, J. Virol., 90, 8924, 10.1128/JVI.01429-16 Sisk, 2018, Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors, J. Gen. Virol., 99, 619, 10.1099/jgv.0.001047 Bernal-Bello, 2020, Imatinib might constitute a treatment option for lung involvement in COVID-19, Autoimmun. Rev., 19, 102565, 10.1016/j.autrev.2020.102565 Garraud, 2016, Plasma therapy against infectious pathogens, as of yesterday, today and tomorrow, Transfus. Clin. Biol., 23, 39, 10.1016/j.tracli.2015.12.003 Cheng, 2004, Use of convalescent plasma therapy in {SARS} patients in Hong Kong, Eur. J. Clin. Microbiol. Infect. Dis., 24, 44, 10.1007/s10096-004-1271-9 Brown, 2018, Anti–Ebola virus antibody levels in convalescent plasma and viral load after plasma infusion in patients with Ebola virus disease, J. Infect. Dis., 218, 555, 10.1093/infdis/jiy199 Zhu, 2020, Use of convalescent plasma in COVID-19 patients in China, Transfus. Clin. Biol., 27, 168, 10.1016/j.tracli.2020.05.001 Rojas, 2020, Convalescent plasma in Covid-19: possible mechanisms of action, Autoimmun. Rev., 19, 102554, 10.1016/j.autrev.2020.102554 Duan, 2020, Effectiveness of convalescent plasma therapy in severe COVID-19 patients, Proc. Natl. Acad. Sci., 117, 9490, 10.1073/pnas.2004168117 Shen, 2020, Treatment of 5 critically ill patients with COVID-19 with convalescent plasma, JAMA., 323, 1582, 10.1001/jama.2020.4783 Zhang, 2020, Treatment with convalescent plasma for critically ill patients with severe acute respiratory syndrome coronavirus 2 infection, Chest., 158, e9, 10.1016/j.chest.2020.03.039 Sempowski, 2020, Pandemic preparedness: developing vaccines and therapeutic antibodies for COVID-19, Cell, 181, 1458, 10.1016/j.cell.2020.05.041 Marano, 2015, Human T-lymphotropic virus and transfusion safety: does one size fit all?, Transfusion, 56, 249, 10.1111/trf.13329 Ju, 2020 Shu, 2017, GISAID: global initiative on sharing all influenza data – from vision to reality, Eurosurveillance., 22, 30494, 10.2807/1560-7917.ES.2017.22.13.30494 World Health Organization T. Thanh Le, Z. Andreadakis, A. Kumar, R. Gómez Román, S. Tollefsen, M. Saville, S. Mayhew, The COVID-19 vaccine development landscape, Nat. Rev. Drug Discov. 19 (2020) 305–306, https://doi.org/10.1038/d41573-020-00073-5. Hung, 2020, Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial, Lancet, 395, 1695, 10.1016/S0140-6736(20)31042-4 Ledford, 2020, Dozens of coronavirus drugs are in development - what happens next?, Nature, 581, 247, 10.1038/d41586-020-01367-9